Evategrel (CG-0255) vs Sumecigrel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atherosclerotic Cardiovascular Disease

Shared mechanism: P2Y12 platelet receptor · full Atherosclerotic Cardiovascular Disease pipeline

Evategrel (CG-0255)

Developed by Shanghai CureGene Pharmaceutical

Phase 1 in Atherosclerotic Cardiovascular Diseasesmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Sumecigrel

Developed by Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and partners

Phase 3 in Atherosclerotic Cardiovascular Diseasesmall molecule
Partial signal

NCT03599284 · Phase 2 · completed

This dose-exploring Phase 2 trial randomly assigned 279 patients with coronary artery disease undergoing percutaneous coronary intervention to one of three vicagrel doses or to clopidogrel, all with aspirin, under double-blind, triple-dummy treatment. The primary measure was inhibition of platelet aggregation at day 28. Inhibition ranged from 30.19% to 45.61% with vicagrel against 32.55% with clopidogrel, and the authors report the groups as comparable (P=0.0694). The trial compared doses without a prespecified non-inferiority margin, so the paper does not show whether the primary comparison was met or missed, and the result is shown as unclear. The figures come from the peer-reviewed paper (Zhao et al., Eur Heart J Cardiovasc Pharmacother 2022).

Next expected readout: December 2026 · NCT06577519 (registry estimate)

Reported efficacy

Inhibition of platelet aggregation (28 days after treatment): Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin. (unclear)

Result source: NCT03599284

Results for Atherosclerotic Cardiovascular Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEvategrel (CG-0255)Sumecigrel
LDL-C, % change—Not reported—Trial running · NCT06577519
Non-HDL-C, % change—Not reported—Trial running · NCT06577519
ApoB, % change—Not reported—Trial running · NCT06577519
Lp(a), % change—Not reported—Trial running · NCT06577519
3-point MACE (% with event)—Not reported—Trial running · NCT06577519

LDL-C, % change

Evategrel (CG-0255)
—Not reported
Sumecigrel
—Trial running · NCT06577519

Non-HDL-C, % change

Evategrel (CG-0255)
—Not reported
Sumecigrel
—Trial running · NCT06577519

ApoB, % change

Evategrel (CG-0255)
—Not reported
Sumecigrel
—Trial running · NCT06577519

Lp(a), % change

Evategrel (CG-0255)
—Not reported
Sumecigrel
—Trial running · NCT06577519

3-point MACE (% with event)

Evategrel (CG-0255)
—Not reported
Sumecigrel
—Trial running · NCT06577519
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Evategrel (CG-0255): no structured comparison results are available for Atherosclerotic Cardiovascular Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sumecigrel
Primary, inhibition of ADP-induced platelet aggregation (%IPA) at day 28: vicagrel 20/5 mg 30.19%, 24/6 mg 35.02%, 30/7.5 mg 45.61%, clopidogrel 32.55%; the paper reports these as comparable across all groups (P=0.0694) and sets no non-inferiority margin. NCT03599284 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Evategrel (CG-0255)'s landscape · Sumecigrel's landscape